Modern pharmaceutical company assured this Tuesday that its budding vaccine for the prevention of COVID-19, the mRNA-1273, “Can generate neutralizing antibodies in the elderly and older adults at levels comparable with (the one it generates in) young adults,” as suggested by provisional data published in the journal The New England Journal of Medicine.
“These provisional data from Phase 1 suggest that mRNA-1273, our candidate to become a vaccine for the prevention of COVID-19, can generate neutralizing antibodies in older adults and the elderly at levels comparable to younger adults, ”said Tal Zaks, MD, Ph. D., Moderna’s medical director, quoted in the note.
Last July, the US pharmaceutical company announced the beginning of phase 3 of the trials of its experimental vaccine against the disease of the COVID-19 for the general population and that includes the participation of 30,000 volunteers; and his CEO, Stephen Bancel, He said in the middle of the month that they could find out if his vaccine is effective in October, although he considered that the expected data on the final phase of its development will most likely arrive in November.
“Given the greater morbidity and mortality of COVID-19 in elderly and elderly, these data give us optimism in demonstrating the protection of mRNA-1273 in this population, “added Zaks.
Moderna explains that this interim analysis evaluated a Phase 1 vaccination program that includes the inoculation of two doses of mRNA-123, which were administered with 28 days difference to 40 patients divided into two groupss, one aged between 56 and 70 years and another over 71 years.
Related: All volunteers who received the COVID-19 vaccine developed an immune response, report Russian authorities
Volunteers were given doses of 25 micrograms (µg) and others of 100 µg. Analyzes carried out one month after the administration of the second dose revealed that higher neutralizing antibody titers were generated at the 100 µg doses.
The pharmaceutical underlines that, in general, both doses were well tolerated and did not generate serious side effects.
Moderna cited headaches, myalgia, chills, and injection site pain as the most common, “most of which were mild to moderate in intensity and of limited duration.”
However, it points out that after the second vaccination “there were two serious systemic adverse events”: fever in a participant in the group between 56 and 70 years who received the 25 µg dose and fatigue in a participant in the group older than 70 years. who received the 100 µg dose.
Related: The world exceeds one million deaths from coronavirus
Although Moderna pointed out that “Revealed no pattern of concern”.